Form 10-Q · Quarterly report
Best Buy 10-Q, filed Sep 4, 2026
- Filed
- CIK
- 0000764478
- Accession no.
- 0000764478-26-000042
Summary
Best Buy reported fiscal 2027 second-quarter revenue of $9.779 billion, comparable sales growth of 4.1%, net earnings of $315 million, and diluted EPS of $1.48. The company received $34 million in IEEPA tariff refunds after the U.S. Supreme Court ruled on February 20, 2026 that such tariffs were unauthorized, with another $41 million refunded on September 2, 2026.
Key points
- Best Buy's fiscal second-quarter revenue rose 3.6% to $9.779 billion, and comparable sales rose 4.1%.
- Net earnings were $315 million and diluted EPS was $1.48, compared with $186 million and $0.87 a year earlier.
- Best Buy received $34 million in IEEPA tariff refunds in the second quarter and an additional $41 million on September 2, 2026, to be recorded in the third quarter of fiscal 2027.
- Beginning in fiscal 2027, Best Buy reclassified credit card revenue and digital content revenue into services revenue, without affecting previously reported total revenue, comparable sales, net earnings, or cash flows.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management's Discussion Overview We are driven by our purpose to enrich lives through technology and our vision to personalize and humanize technology solutions for every stage of life. We accomplish this by leveraging our combination of tech expertise and a human touch to meet our customers’ everyday needs, whether they come to us online, visit our stores or invite us into their homes. We have two reportable segments: Domestic and International. The Domestic segment is comprised of our operations in all states, districts and territories of the U.S. and our Best Buy Health business. The International segment is comprised of all our operations in Canada. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.